Cargando…
Eltoprazine modulated gamma oscillations on ameliorating L‐dopa‐induced dyskinesia in rats
AIM: Parkinson's disease (PD) is a pervasive neurodegenerative disease, and levodopa (L‐dopa) is its preferred treatment. The pathophysiological mechanism of levodopa‐induced dyskinesia (LID), the most common complication of long‐term L‐dopa administration, remains obscure. Accumulated evidence...
Autores principales: | Bi, Yuewei, Wang, Pengfei, Yu, Jianshen, Wang, Zhuyong, Yang, Hanjie, Deng, Yuhao, Guan, Jianwei, Zhang, Wangming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493666/ https://www.ncbi.nlm.nih.gov/pubmed/37122156 http://dx.doi.org/10.1111/cns.14241 |
Ejemplares similares
-
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
por: Svenningsson, Per, et al.
Publicado: (2015) -
Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016) -
Identification of PBK as a hub gene and potential therapeutic target for medulloblastoma
por: Deng, Yuhao, et al.
Publicado: (2022) -
Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018) -
Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017)